Put AI to work
June 26-27, 2017: Training
June 27-29, 2017: Tutorials & Conference
New York, NY

Cognitive mobile healthcare for the patient and physician

Michael Nova (Pathway Genomics)
11:05am11:45am Thursday, June 29, 2017
Verticals and applications
Location: Gramercy East/West Level: Beginner
Secondary topics:  Health care, Machine Learning, Natural Language
Average rating: *****
(5.00, 1 rating)

Prerequisite Knowledge

  • A basic understanding of AI and precision medicine

What you'll learn

  • Understand how AI is impacting healthcare big data, how mobile devices using AI will leverage telemedicine for the masses, and why precession medicine is important


Every two years, the world’s database doubles; medical information, specifically, doubles every three years. By 2020, global healthcare data will double every 73 days, with 80% of the data being unstructured. Healthcare costs in the United States currently exceed 17% of the GDP and continue to rise, and patients are now more responsible for the cost of healthcare services. In addition, because of increased access to high-quality general medical information and IoT device data, users are much more informed and demanding of superior healthcare services. This has lead to the notion of “precision” medicine, where “one size fits all” care is now becoming a thing of the past.

Precision medicine is largely a big data and systems problem, with many different types of “siloed” healthcare information, such as lab results, genetic tests, IoT and wearables data, and insurance information, needing to be collected and intelligently codified on an individual user basis. But data is worthless unless it can be analyzed and acted on. Patients and physicians deserve accurate and actionable recommendations on any personal healthcare data to truly implement “precision” medicine. Michael Nova explains why cognitive computing and artificial intelligence that can dynamically learn using any healthcare data will dramatically impact precision healthcare.

A powerful driver of value in healthcare is that better outcomes often go hand in hand with lower total care-cycle costs. Spending more on prevention, early detection, and monitoring of chronic diseases (and better diagnosis of diseases), for example, spares patients suffering and often leads to less complex and less expensive later care. As an example, the use of telemedicine in the UK has led to a 45% drop in mortality rates and a 20% reduction in emergency hospital admissions. It is a well-known fact that 80% of all chronic healthcare costs, from diseases such as obesity, diabetes, cardiovascular disease, and cancer, is preventable.

With the above caveats in mind, the use of artificial intelligence that can read unstructured data automatically, collate it, make personalized recommendations on the myriad of healthcare data streams (cognitive medicine), and dynamically learn will improve medical care. A natural language processing AI has already shown utility in oncology programs at Memorial Sloan Kettering and other institutions.

Michael explores the only mobile consumer application using artificial intelligence and machine learning (including IBM Watson) that collects and manages any type of healthcare information, such as genetics data and electronic health records, to give dynamic precision wellness and medical recommendations to the user or physician.

Photo of Michael Nova

Michael Nova

Pathway Genomics

Michael Nova is the chief innovation officer at Pathway Genomics and was a founding team member of the company. Michael is the inventor of the Pathway-IBM Watson machine learning AI mobile application Panorama/OME as well as Pathway’s entire wellness (Pathway FIT, Healthy Weight, SkinFIT), cardiac, and mental health lines of genetic testing products. Michael has executed major corporate alliances with companies such as Medco/ESI, PepsiCo, DASA (Brazil), Biogenetika (Brazil), Achibadem (Turkey), IHH/Parkway (Singapore), IBM, Florida Hospital Group, Equinox Health, and many others. Previously, Michael was the founder and CEO of Discovery Partners Inc., which completed a successful $150M IPO and marketed wireless drug discovery technology and radiofrequency combinatorial chemistry to large pharmaceutical companies, where he developed the original “barcode on bead” patents used by many diagnostic and DNA companies. He then founded the wireless sensory network company Graviton, where he was responsible for raising $60 million in capital from venture groups such as Kleiner Perkins and InQtel and large corporations, such as Motorola and Qualcomm. He began his scientific career as a research associate at the Salk Institute in the laboratory of Nobel Laureate Roger Guillemin, where he studied the genetics and proteomics of human growth factors and cancers.

Michael won the 2005 World Economic Forum (WEF) Technology Pioneer Award and was the physician of record on the first person ever to have their entire genome sequenced by Illumina. He is a member of the IBM Watson Advisory Board, the Metagenics Scientific Advisory Board, the Salk Institute NeuroAI group, and the Longevity Org Advisory Board. Michael has over 30 issued and 45 pending patents; and he has numerous publications in peer-reviewed journals. He is a board-certified dermatologist and dermatopathologist, licensed in California, with degrees in biochemistry, physics, computer science, and medicine. In his minimal spare time, Michael likes to surf big waves in Indonesia and Mexico, and he also helped build a WHO-sanctioned basic care clinic in the Fijian town of Nabila.